Skip to main content

Ergoloid Mesylates Dosage

Medically reviewed by Last updated on Aug 16, 2021.

Applies to the following strengths: 1 mg; 1 mg/mL; 0.5 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Dementia

1 mg orally 3 times a day

-The decision to treat an individual with an ill-defined decline in mental capacity may result in missing underlying conditions that could be reversible and treatable; great care should be exercised to exclude delirium secondary to systemic disease, primary neurological disease, or primary disturbance of mood as possible conditions prior to treatment.
-Continued clinical evaluation is necessary during treatment as the patient's condition may evolve sufficiently to allow for a specific diagnosis and specific alternative treatment.

Use: Symptomatic relief of an idiopathic decline in mental capacity effecting self-care, mood, motivation, cognitive and interpersonal skills.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Take orally 3 times a day

Storage requirements: Protect from light

-As treatment with this drug means target symptoms are of unknown etiology, careful diagnosis should be attempted prior to prescribing.
-Once therapy begins, alleviation of symptoms may not be observed for 3 to 4 weeks.
-Modest efficacy was shown on the SCAG (Sandoz Clinical Assessment-Geriatric) scale including improvements to mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome (ness), and overall impression of clinical status at 12-weeks.

-Monitor for reversible and treatable conditions
-Continually assess and rate improvements to ensure any initial benefit persists with time.

Patient advice:
-Transient nausea and gastric disturbances may occur.
-This drug does not possess the vasoconstrictor properties of natural ergot alkaloids.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.